EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO

Venkata K Yellepeddi iD, John Porter Hunt, Danielle J Green iD, Autumn McKnite iD, Aviva Whelan iD, Kevin Watt

CPT: Pharmacometrics & Systems Pharmacology · 2024-09 · 13 (9) · 1542-1553

DOI: 10.1002/psp4.13199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 21.07.2024. Verfasst von Venkata K Yellepeddi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Amiodarone, Extracorporeal Membrane Oxygenation, Models, Biological, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of Child Health and Human Development, National Institutes of Health, NICHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass device commonly used to treat cardiac arrest in children. The American Heart Association guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care recommend using amiodarone as a first‐line agent to treat ventricular arrhythmias in children with cardiac arrest. However, there are no dosing recommendations for amiodarone to treat ventricular arrhythmias in pediatric patients on ECMO. Amiodarone has a high propensity for adsorption to the ECMO components due to its physicochemical properties leading to altered pharmacokinetics (PK) in ECMO patients. The change in amiodarone PK due to interaction with ECMO components may result in a difference in optimal dosing in patients on ECMO when compared with non‐ECMO patients. To address this clinical knowledge gap, a physiologically‐based pharmacokinetic model of amiodarone was developed in adults and scaled to children, followed by the addition of an ECMO compartment. The pediatric model included ontogeny functions of cytochrome P450 (CYP450) enzyme maturation across various age groups. The ECMO compartment was parameterized using the adsorption data of amiodarone obtained from ex vivo studies. Model predictions captured observed concentrations of amiodarone in pediatric patients with ECMO well with an average fold error between 0.5 and 2. Model simulations support an amiodarone intravenous (i.v) bolus dose of 22 mg/kg (neonates), 13 mg/kg (infants), 8 mg/kg (children), and 6 mg/kg (adolescents). This PBPK modeling approach can be applied to explore the dosing of other drugs used in children on ECMO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneExtracorporeal Membrane OxygenationModels, BiologicalAnti-Arrhythmia AgentsHumansChildChild, PreschoolInfantAdolescentInfant, NewbornAdultMaleDose-Response Relationship, DrugFemaleCytochrome P-450 Enzyme SystemAge Factors

Substanzen

AmiodaroneAnti-Arrhythmia AgentsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
  • Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Venkata K Yellepeddi, Danielle J Green, Autumn McKnite, Aviva Whelan

Förderung

  • National Institute of Child Health and Human Development, National Institutes of Health
  • NICHD NIH HHS
  • NHLBI NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Yellepeddi, V. K., Hunt, J. P., Green, D. J., McKnite, A., Whelan, A., & Watt, K. (2024). A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO. CPT: Pharmacometrics & Systems Pharmacology, 13(9), 1542-1553. https://doi.org/10.1002/psp4.13199

Vancouver

Yellepeddi VK, Hunt JP, Green DJ, McKnite A, Whelan A, Watt K. A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(9):1542-1553. doi:10.1002/psp4.13199

BibTeX
@article{Yellepeddi2024,
  author = {Yellepeddi, Venkata K and Hunt, John Porter and Green, Danielle J and McKnite, Autumn and Whelan, Aviva and Watt, Kevin},
  title = {A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  volume = {13},
  number = {9},
  pages = {1542--1553},
  doi = {10.1002/psp4.13199}
}
Kostenlos starten →